Splendor in the grass? A pilot study assessing the impact of medical marijuana on executive function

Frontiers in Pharmacology

Volumn 7, Issue OCT, 2016, Pages

  Gruber, Staci A ^a,b   Sagar, Kelly A ^a,b   Dahlgren, Mary K ^a,c   Racine, Megan T ^a   Smith, Rosemary T ^a   Lukas, Scott E ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TUFTS UNIVERSITY   (United States)

Author keywords

Cannabidiol; Cannabis; Cognition; Executive function; Medical marijuana; THC

Indexed keywords

MEDICAL CANNABIS;

ADULT; AGED; ARTICLE; BARRATT IMPULSIVENESS SCALE; BECK ANXIETY INVENTORY; BECK DEPRESSION INVENTORY; CHRONIC PAIN; CLINICAL ARTICLE; DEPRESSION; EXECUTIVE FUNCTION; FEMALE; HUMAN; IMPULSIVENESS; LONGITUDINAL STUDY; MALE; PILOT STUDY; PITTSBURGH SLEEP QUALITY INDEX; PROFILE OF MOOD STATES; QUALITY OF LIFE; RESPONSE TIME; SHORT FORM 36; SLEEP DISORDER; STROOP TEST; TRAIL MAKING TEST;

EID: 84995403731     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2016.00355     Document Type: Article

References (99)

1. ArcView Market Research (2016). The State of Legal Marijuana Markets, 2nd Edn. Available online at: http://www.arcviewmarketresearch.com
2. Auer, R., Vittinghoff, E., Yaffe, K., Kunzi, A., Kertesz, S. G., Levine, D. A., et al. (2016). Association between lifetime marijuana use and cognitive function in middle age: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. JAMA Intern. Med. 176, 352-361. doi: 10.1001/jamainternmed.2015.7841
3. Ballantyne, J. C., and Shin, N. S. (2008). Efficacy of opioids for chronic pain: a review of the evidence. Clin. J. Pain 24, 469-478. doi: 10.1097/AJP.0b013e31816b2f26
4. Baron, E. P. (2015). Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it's been.. Headache 55, 885-916. doi: 10.1111/head.12570
5. Beck, A. T., and Steer, R. A. (1990). Manual for the Beck Anxiety Inventory. San Antonio, TX: Psychological Corporation.
6. Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., and Erbaugh, J. (1961). An inventory for measuring depression. Arch. Gen. Psychiatry 4, 561-571. doi: 10.1001/archpsyc.1961.01710120031004
7. Becker, M. P., Collins, P. F., and Luciana, M. (2014). Neurocognition in college-aged daily marijuana users. J. Clin. Exp. Neuropsychol. 36, 379-398. doi: 10.1080/13803395.2014.893996
8. Beglinger, L. J., Gaydos, B., Tangphao-Daniels, O., Duff, D., Kareken, D. A., Crawford, J., et al. (2005). Practice effects and the use of alternate forms in serial neuropsychological testing. Arch. Clin. Neuropsychol. 20, 517-529. doi: 10.1016/j.acn.2004.12.003
9. Berg, E. A. (1948). A simple objective technique for measuring flexibility in thinking. J. Gen. Psychol. 39, 15-22. doi: 10.1080/00221309.1948.9918159
10. Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., et al. (2010). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35, 764-774. doi: 10.1038/npp.2009.184
11. Birch, E. A. (1889). The use of Indian hemp in the treatment of chronic chloral and chronic opium poisoning. Lancet 133, 625. doi: 10.1016/S0140-6736(00)30567-0
12. Blessing, E. M., Steenkamp, M. M., Manzanares, J., and Marmar, C. R. (2015). Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics 12, 825-836. doi: 10.1007/s13311-015-0387-1
13. Booth, M. (2003). Cannabis: A History. New York, NY: Picador.
14. Borelli, F., Fasolino, I., Romano, B., Capasso, R., Maiello, F., Coppola, D., et al. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem. Pharmacol. 85, 1306-1316. doi: 10.1016/j.bcp.2013.01.017
15. Borgwardt, S. J., Allen, P., Bhattacharyya, S., Fusar-Poli, P., Crippa, J. A., Seal, M. L., et al. (2008). Neural basis of delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol. Psychiatry 64, 966-973. doi: 10.1016/j.biopsych.2008.05.011
16. Boychuk, D. G., Goddard, G., Mauro, G., and Orellana, M. F. (2015). The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review. J. Oral Facial Pain Headache 29, 7-14. doi: 10.11607/ofph.1274
17. Braga, R. J., Burdick, K. E., Derosse, P., and Malhotra, A. K. (2012). Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder. Psychiatry Res. 200, 242-245. doi: 10.1016/j.psychres.2012.05.025
18. Buysse, D. J., Reynolds, C. F. 3rd., Monk, T. H., Berman, S. R., and Kupfer, D. J. (1989). The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 28, 193-213. doi: 10.1016/0165-1781(89)90047-4
19. Center for Behavioral Health Statistics Quality (2015). Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15-4927, NSDUH Series H-50). Available online at: http://www.samhsa.gov/data/(Accessed June 16, 2016).
20. Centers for Disease Control Prevention, National Center for Health, Statistics National Vital Statistics System Mortality File. (2015). Number and Age-Adjusted Rates of Drug-poisoning Deaths Involving Opioid Analgesics and Heroin: United States, 2000-2014. Atlanta, GA: Center for Disease Control and Prevention. Available online at http://www.cdc.gov/nchs/data/health_policy/AADR_drug_poisoning_involving_OA_Heroin_US_2000-2014.pdf
21. Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., et al. (1991). Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol. Biochem. Behav. 40, 701-708. doi: 10.1016/0091-3057(91)90386-G
22. Cousijn, J., Watson, P., Koenders, L., Vingerhoets, W. A., Goudriaan, A. E., and Wiers, R. W. (2013). Cannabis dependence, cognitive control and attentional bias for cannabis words. Addict. Behav. 38, 2825-2832. doi: 10.1016/j.addbeh.2013.08.011
23. Crane, N. A., Schuster, R. M., and Gonzalez, R. (2013). Preliminary evidence for a sex-specific relationship between amount of cannabis use and neurocognitive performance in young adult cannabis users. J. Int. Neuropsychol. Soc. 19, 1009-1015. doi: 10.1017/S135561771300088X
24. Crane, N. A., Schuster, R. M., Mermelstein, R. J., and Gonzalez, R. (2015). Neuropsychological sex differences associated with age of initiated use among young adult cannabis users. J. Clin. Exp. Neuropsychol. 37, 389-401. doi: 10.1080/13803395.2015.1020770
25. Crean, R. D., Crane, N. A., and Mason, B. J. (2011). An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J. Addict. Med. 5, 1-8. doi: 10.1097/ADM.0b013e31820c23fa
26. Dahlgren, M. K., Sagar, K. A., Racine, M. T., Dreman, M. W., and Gruber, S. A. (2016). Marijuana use predicts cognitive performance on tasks of executive function. J. Stud. Alcohol Drugs 77, 298-308. doi: 10.15288/jsad.2016.77.298
27. Degenhardt, L., Lintzeris, N., Campbell, G., Bruno, R., Cohen, M., Farrell, M., et al. (2015). Experience of adjunctive cannabis use for chronic non-cancer pain: findings from the Pain and Opioids IN Treatment (POINT) study. Drug Alcohol Depend. 147, 144-150. doi: 10.1016/j.drugalcdep.2014.11.031
28. Department of Justice (2016a). Denial of Petition to Initiate Proceedings to Reschedule Marijuana (21 CFR Chapter II, Docket No. DEA-427). Springfield, VA: Drug Enforcement Administration.
29. Department of Justice (2016b). Applications to Become Registered Under the Controlled Substances Act to Manufacture Marijuana to Supply Researchers in the United States (21 CFR Part 1301, Docket No. DEA-447). Springfield, VA: Drug Enforcement Administration.
30. Deshpande, A., Mailis-Gagnon, A., Zoheiry, N., and Lakha, S. F. (2015). Efficacy and adverse effects of medical marijuana for chronic noncancer pain: systematic review of randomized controlled trials. Can. Fam. Physician 61, E372-E381.
31. Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., et al. (2016). Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 15, 170-178. doi: 10.1016/S1474-4422(15)00379-8
32. Dougherty, D. M., Mathias, C. W., Dawes, M. A., Furr, R. M., Charles, N. E., Liguori, A., et al. (2013). Impulsivity, attention, memory, and decision-making among adolescent marijuana users. Psychopharmacology (Berl). 226, 307-319. doi: 10.1007/s00213-012-2908-5
33. Ehrenreich, H., Rinn, T., Kunert, H. J., Moeller, M. R., Poser, W., Schilling, L., et al. (1999). Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology (Berl). 142, 295-301. doi: 10.1007/s002130050892
34. Eisenberg, E., Ogintz, M., and Almog, S. (2014). The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study. J. Pain Palliat. Care Pharmacother. 28, 216-225. doi: 10.3109/15360288.2014.941130
35. ElSohly, M. A., Mehmedic, Z., Foster, S., Gon, C., Chandra, S., and Church, J. C. (2016). Changes in cannabis potency over the last 2 decades (1995-2014): analysis of current data in the United States. Biol. Psychiatry 79, 613-619. doi: 10.1016/j.biopsych.2016.01.004
36. Englund, A., Morrison, P. D., Nottage, J., Hague, D., Kane, F., Bonaccorso, S., et al. (2013). Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J. Psychopharmacol. 27, 19-27. doi: 10.1177/0269881112460109
37. Englund, A., Atakan, Z., Kralj, A., Tunstall, N., Murray, R., and Morrison, P. (2016). The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. J. Psychopharmacol. (Oxford). 30, 140-151. doi: 10.1177/0269881115615104
38. Flachenecker, P., Henze, T., and Zettl, U. K. (2014). Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice-results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur. Neurol. 71, 271-279. doi: 10.1159/000357427
39. Fontes, M. A., Bolla, K. I., Cunha, P. J., Almeida, P. P., Jungerman, F., Laranjeira, R. R., et al. (2011). Cannabis use before age 15 and subsequent executive functioning. Br. J. Psychiatry 198, 442-447. doi: 10.1192/bjp.bp.110.077479
40. Fried, P. A., Watkinson, B., and Gray, R. (2005). Neurocognitive consequences of marihuana-a comparison with pre-drug performance. Neurotoxicol. Teratol. 27, 231-239. doi: 10.1016/j.ntt.2004.11.003
41. Giacoppo, S., Soundara Rajan, T., Galuppo, M., Pollastro, F., Grassi, G., Bramanti, P., et al. (2015). Purified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis. Eur. Rev. Med. Pharmacol. Sci. 19, 4906-4919.
42. Giedd, J. N., Blumenthal, J., Jeffries, N. O., Castellanos, F. X., Liu, H., Zijdenbos, A., et al. (1999). Brain development during childhood and adolescence: a longitudinal MRI study. Nat. Neurosci. 2, 861-863. doi: 10.1038/13158
43. Grinspoon, L., and Bakalar, J. B. (1997). Marihuana: The Forbidden Medicine. New Haven, CT: Yale University Press.
44. Gruber, S. A., Dahlgren, M. K., Sagar, K. A., Gönenc, A., and Killgore, W. D. (2012b). Age of onset of marijuana use impacts inhibitory processing. Neurosci. Lett. 511, 89-94. doi: 10.1016/j.neulet.2012.01.039
45. Gruber, S. A., Dahlgren, M. K., Sagar, K. A., Gonenc, A., and Lukas, S. E. (2014). Worth the wait: effects of age of onset of marijuana use on white matter and impulsivity. Psychopharmacology (Berl). 231, 1455-1465. doi: 10.1007/s00213-013-3326-z
46. Gruber, S. A., Sagar, K. A., Dahlgren, M. K., Racine, M., and Lukas, S. E. (2012a). Age of onset of marijuana use and executive function. Psychol. Addict. Behav. 26, 496-506. doi: 10.1037/a0026269
47. Gul, A., and Humphreys, G. W. (2015). Practice and colour-word integration in Stroop interference. Psicológica 36, 37-67.
48. Hanson, K. L., Thayer, R. E., and Tapert, S. F. (2014). Adolescent marijuana users have elevated risk-taking on the balloon analog risk task. J. Psychopharmacol. (Oxford). 28, 1080-1087. doi: 10.1177/0269881114550352
49. Haroutounian, S., Ratz, Y., Ginosar, Y., Furmanov, K., Saifi, F., Meidan, R., et al. (2016). The effect of medicinal cannabis on pain and quality of life outcomes in chronic pain: a prospective open-label study. Clin. J. Pain. doi: 10.1097/ajp.0000000000000364. [Epub ahead of print].
50. Izzo, A. A., Capasso, R., Aviello, G., Borrelli, F., Romano, B., Piscitelli, F., et al. (2012). Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Br. J. Pharmacol. 166, 1444-1460. doi: 10.1111/j.1476-5381.2012.01879.x
51. Jackson, N. J., Isen, J. D., Khoddam, R., Irons, D., Tuvblad, C., Iacono, W. G., et al. (2016). Impact of adolescent marijuana use on intelligence: results from two longitudinal twin studies. Proc. Natl. Acad. Sci. U.S.A. 113, E500-E508. doi: 10.1073/pnas.1516648113
52. Jacobus, J., Squeglia, L. M., Infante, M. A., Castro, N., Brumback, T., Meruelo, A. D., et al. (2015). Neuropsychological performance in adolescent marijuana users with co-occurring alcohol use: a three-year longitudinal study. Neuropsychology 29, 829-843. doi: 10.1037/neu0000203
53. Jacobus, J., and Tapert, S. F. (2014). Effects of cannabis on the adolescent brain. Curr. Pham. Des. 20, 2186-2193. doi: 10.2174/13816128113199990426
54. Johnston, L., O'Malley, P., Miech, R., Bachman, J., and Schulenberg, J. (2015). Monitoring the Future National Survey Results on Drug Use: 1975-2015: Overview: Key Findings on Adolescent Drug Use. Ann Arbor, MI: Institute for Social Research, The University of Michigan.
55. Joy, J. E., Watson, S. J., and Benson, J. A. (1999). Marijuana and Medicine: Assessing the Science Base. Washington, DC: National Academy Press.
56. Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., et al. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry 2:e94. doi: 10.1038/tp.2012.15
57. Lezak, M. D., Howieson, D. B., and Loring, D. W. (2004). Neuropsychological Assessment, 4th Edn. Oxford: Oxford University Press.
58. Lisdahl, K. M., Gilbart, E. R., Wright, N. E., and Shollenbarger, S. (2013). Dare to delay? The impacts of adolescent alcohol and marijuana use on cognition, brain structure, and function. Front. Psychiatry 4:53. doi: 10.3389/fpsyt.2013.00053
59. Lisdahl, K. M., and Price, J. S. (2012). Increased marijuana use and gender predict poorer cognitive functioning in adolescents and emerging adults. J. Int. Neuropsychol. Soc. 18, 678-688. doi: 10.1017/S1355617712000276
60. Lisdahl, K. M., Wright, N. E., Kirchner-Medina, C., Maple, K. E., and Shollengarger, S. (2014). Considering cannabis: the effects of regular cannabis use on neurocognition in adolescents and young adults. Curr. Addict. Reports 1, 144-156. doi: 10.1007/s40429-014-0019-6
61. MacLeod, C. M. (1991). Half a century of research on the stroop effect: an integrative review. Psychol. Bull. 109, 163-203. doi: 10.1037/0033-2909.109.2.163
62. Medina, K. L., Hanson, K. L., Schweinsburg, A. D., Cohen-Zion, M., Nagel, B. J., and Tapert, S. F. (2007). Neuropsychological functioning in adolescent marijuana users: subtle deficits detectable after a month of abstinence. J. Int. Neuropsychol. Soc. 13, 807-820. doi: 10.1017/S1355617707071032
63. Meier, M. H., Caspi, A., Ambler, A., Harrington, H., Houts, R., Keefe, R. S., et al. (2012). Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc. Natl. Acad. Sci. U.S.A. 109, E2657-E2664. doi: 10.1073/pnas.1206820109
64. Mokrysz, C., Landy, R., Gage, S. H., Munafo, M. R., Rosier, J. P., and Curran, H. V. (2016). Are IQ and educational outcomes in teenagers related to their cannabis use? A prospective cohort study. J. Psychopharm. 30, 159-168. doi: 10.1177/0269881115622241
65. Morgan, C. J., Gardener, C., Schafer, G., Swan, S., Demarchi, C., Freeman, T. P., et al. (2012). Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol. Med. 42, 391-400. doi: 10.1017/S0033291711001322
66. Morgan, C. J., Schafer, G., Freeman, T. P., and Curran, H. V. (2010). Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br. J. Psychiatry 197, 285-290. doi: 10.1192/bjp.bp.110.077503
67. Moriarty, O., McGuire, B. E., and Finn, D. P. (2011). The effect of pain on cognitive function: a review of clinical and preclinical research. Prog. Neurobiol. 93, 385-404. doi: 10.1016/j.pneurobio.2011.01.002
68. Nunberg, H., Kilmer, B., Pacula, R. L., and Burgdorf, J. (2013). An analysis of applicants presenting to a medical marijuana specialty practice in California. J. Drug Policy Anal. 4:1. doi: 10.2202/1941-2851.1017
69. Patti, F., Messina, S., Solaro, C., Amato, M. P., Bergamaschi, R., Bonavita, S., et al. (2016). Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J. Neurol Neurosurg. Psychiatry. 87, 944-951. doi: 10.1136/jnnp-2015-312591
70. Patton, J. H., Stanford, M. S., and Barratt, E. S. (1995). Factor structure of the Barratt impulsiveness scale. J. Clin. Psychol. 51, 768-774.
71. Pollock, V., Cho, D. W., Reker, D., and Volavka, J. (1979). Profile of mood states: the factors and their physiological correlates. J. Nerv. Ment. Dis. 167, 612-614. doi: 10.1097/00005053-197910000-00004
72. Pope, H. G., Gruber, A. J., Hudson, J. I., Cohane, G., Huestis, M. A., and Yurgelun-Todd, D. (2003). Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend. 69, 303-310. doi: 10.1016/S0376-8716(02)00334-4
73. Potter, S. O. L. (1917). "Cannabis," in Therapeutics, Materia Medica, and Pharmacy; The Special Therapeutics of Diseases and Symptoms, the Physiological and Therapeutical Actions of Drugs, The Modern Materia Medica, Official and Practical Pharmacy, Prescription Writing, and Antidotal and Antagonistic Treatment of Poisoning, ed E.H. Funk (Philadelphia, PA: Blakiston's Son & Co), 195-197.
74. Press, C. A., Knupp, K. G., and Chapman, K. E. (2015). Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav. 45, 49-52. doi: 10.1016/j.yebeh.2015.02.043
75. Ringen, P. A., Vaskinn, A., Sundet, K., Engh, J. A., Jonsdottir, H., Simonsen, C., et al. (2010). Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia. Psychol. Med. 40, 1337-1347. doi: 10.1017/S0033291709991620
76. Rosenblum, A., Marsch, L. A., Joseph, H., and Portenoy, R. K. (2008). Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp. Clin. Psychopharmacol. 16, 405-416. doi: 10.1037/a0013628
77. Ryan-Ibarra, S., Induni, M., and Ewing, D. (2015). Prevalence of medical marijuana use in California, 2012. Drug Alcohol Rev. 34, 141-146. doi: 10.1111/dar.12207
78. Sagar, K. A., Dahlgren, M. K., Gönenç, A., Racine, M. T., Dreman, M. W., and Gruber, S. A. (2015). The impact of initiation: early onset marijuana smokers demonstrate altered Stroop performance and brain activation. Dev. Cogn. Neurosci. 16, 84-92. doi: 10.1016/j.dcn.2015.03.003
79. Sagar, K. A., Dahlgren, M. K., Racine, M. T., Dreman, M. W., Olson, D. P., and Gruber, S. A. (2016). Joint effects: a pilot investigation of the impact of bipolar disorder and marijuana use on cognitive function and mood. PLoS ONE 11:e0157060. doi: 10.1371/journal.pone.0157060
80. Shinjyo, N., and Di Marzo, V. (2013). The effect of cannabichromene on adult neural stem/progenitor cells. Neurochem. Int. 63, 432-437. doi: 10.1016/j.neuint.2013.08.002
81. Shuster, R. M., Hoeppner, S. S., Evins, A. E., and Gilman, J. M. (2016). Early onset marijuana use is associated with learning inefficiencies. Neuropsychology 30, 405-415. doi: 10.1037/neu0000281
82. Silver, C. (2016, June 2). Marijuana's $40 Billion Dollar Green Rush. Forbes. Available online at: http://www.forbes.com.
83. Sobell, L. C., Sobell, M. B., Leo, G. I., and Cancilla, A. (1998). Reliability of a timeline method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. Br. J. Addict. 83, 393-402. doi: 10.1111/j.1360-0443.1988.tb00485.x
84. Solowij, N., Jones, K. A., Rozman, M. E., Davis, S. M., Ciarrochi, J., Heaven, P. C., et al. (2012). Reflection impulsivity in adolescent cannabis users: a comparison with alcohol-using and non-substance-using adolescents. Psychopharmacology (Berl). 219, 575-586. doi: 10.1007/s00213-011-2486-y
85. Tait, R. J., Mackinnon, A., and Christensen, H. (2011). Cannabis use and cognitive function: 8-year trajectory in a young adult cohort. Addiction 106, 2195-2203. doi: 10.1111/j.1360-0443.2011.03574.x
86. Tamm, L., Epstein, J. N., Lisdahl, K. M., Molina, B., Tapert, S., Hinshaw, S. P., et al. (2013). Impact of ADHD and cannabis use on executive functioning in young adults. Drug Alcohol Depend. 133, 607-614. doi: 10.1016/j.drugalcdep.2013.08.001
87. Therapeutic Hemp Medical Access Act (2015). Therapeutic Hemp Medical Access Act of 2015. S. 1333, 114th Cong.
88. Valdeolivas, S., Navarrete, C., Cantarero, I., Bellido, M. L., Munoz, E., and Sagredo, O. (2015). Neuroprotective properties of cannabigerol in Huntington's Disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics 12, 185-199. doi: 10.1007/s13311-014-0304-z
89. Vytal, K. E., Cornwell, B. R., Letkiewicz, A. M., Arkin, N. E., and Grillon, C. (2013). The complex interaction between anxiety and cognition: insight from spatial and verbal working memory. Front. Hum. Neurosci. 7:93. doi: 10.3389/fnhum.2013.00093
90. Wachtel, S. R., ElSohly, M. A., Ross, S. A., Ambre, J., and de Wit, H. (2002). Comparison of the subjective effects of δ9-tetrahydrocannabinol and marijuana in humans. Psychopharmacology (Berl). 161, 331-339. doi: 10.1007/s00213-002-1033-2
91. Ware, J. E. Jr., and Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 30, 473-483.
92. Wechsler, D. (1997). Wechsler Adult Intelligence Scale, 3rd Edn. (WAIS-III). San Antonio, TX: Harcourt Assessment.
93. Wechsler, D. (1999). Wechsler Abbreviated Scale of Intelligence. San Antonio, TX: The Psychological Corporation, Hartcourt Brace and Company.
94. Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A., et al. (2015). Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313, 2456-2473. doi: 10.1001/jama.2015.6358
95. Wilkie, G., Sakr, B., and Rizack, T. (2016). Medical marijuana use in oncology: a review. JAMA Oncol. doi: 10.1001/jamaoncol.2016.0155. [Epub ahead of print].
96. Winward, J. L., Hanson, K. L., Tapert, S. F., and Brown, S. A. (2014). Heavy alcohol use, marijuana use, and concomitant use by adolescents are associated with unique and shared cognitive decrements. J. Int. Neuropsychol. Soc. 20, 784-795. doi: 10.1017/S1355617714000666
97. Zeiger, J. S., Haberstick, B. C., Corley, R. P., Ehringer, M. A., Crowley, T. J., Hewitt, J., et al. (2010). Subjective effects to marijuana associated with marijuana use in community and clinical subjects. Drug Alcohol Depend. 109, 161-166. doi: 10.1016/j.drugalcdep.2009.12.026
98. Zuardi, A. W., Crippa, J. A., Hallak, J. E., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., et al. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr. Pharm. Des. 18, 5131-5140. doi: 10.2174/138161212802884681
99. Zuardi, A. W., Crippa, J. A., Hallak, J. E., Pinto, J. P., Chagas, M. H., Rodrigues, G. G., et al. (2009). Cannabidiol for the treatment of psychosis in Parkinson's disease. J. Psychopharmacol. (Oxford). 23, 979-83. doi: 10.1177/0269881108096519